Healthcare inventory risk from make-to-stock production
First written in FY2016. 16 of 21 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2026: 22 of 47 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「Our Group's healthcare business uses make-to-stock production for certain products. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The company continues to describe demand-forecasting and inventory risks while limiting make-to-stock production to certain products. - FY2023RestatedAnnual report
「Our Group's healthcare business uses make-to-stock production for certain products. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The company continues to describe demand-forecasting and inventory risks while limiting make-to-stock production to certain products. - FY2023-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2022-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2021RestatedAnnual report
「Our Group's healthcare business uses make-to-stock production for certain products. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The company continues to describe demand-forecasting and inventory risks while limiting make-to-stock production to certain products. - FY2021-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2021-Q2RestatedAnnual report
「During the second quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2020SoftenedAnnual report
「Our Group's healthcare business uses make-to-stock production for certain products. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The description now limits the scope of make-to-stock production from the entire healthcare business, as previously stated, to “certain products.” The demand-forecasting and inventory risks themselves continue. - FY2020-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period, there were no significant changes in the financial position, operating results or cash flows. There were also no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2020-Q1RestatedAnnual report
「During the first quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2019MaterialisedAnnual report
「Although gross profit increased as sales of products related to “IT Hanabiratake” expanded, the segment loss improved slightly because inventories were written down after the carrying value of assets related to the healthcare business was reviewed in light of their future recoverability.」
In connection with the inventory risk from make-to-stock production, inventories were written down again in the current fiscal year based on a review of the recoverability of assets related to the healthcare business. - FY2019-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period, there were no significant changes in the financial position, operating results or cash flows. There were also no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2019-Q1RestatedAnnual report
「During the first quarter of the consolidated cumulative period, there were no new business or other risks, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2018RestatedAnnual report
「Our Group's healthcare business serves general consumers and therefore uses make-to-stock production. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The company continues to describe demand-forecasting and inventory risks associated with make-to-stock production for general consumers. - FY2018-Q3RestatedAnnual report
「There have been no material changes in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2018-Q2RestatedAnnual report
「There have been no material changes in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2018-Q1RestatedAnnual report
「There are no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company explains that there has been no material change in the healthcare inventory risk arising from make-to-stock production. - FY2017MaterialisedAnnual report
「The impact of a write-down of inventories in the current consolidated fiscal year because sales of raw materials did not progress as planned at the beginning of the fiscal year」
Because raw-material sales fell short of plan, the company recognized a ¥117 million write-down of inventories in the current period, and the inventory risk from make-to-stock production materialized. - FY2017-Q3MaterialisedAnnual report
「The impact of a write-down of raw-material inventories in the third quarter because sales of raw materials did not progress as initially planned」
The company states that the previously described healthcare inventory risk materialized because raw-material sales fell short of plan and raw-material inventories were actually written down. - FY2016First statedAnnual report
「Our Group's healthcare business serves general consumers and therefore uses make-to-stock production. If it makes a significant error in forecasting demand, it may incur inventory risk, which could affect its performance and other results.」
The company describes the inventory risk arising from incorrect demand forecasts because it produces for general consumers on a make-to-stock basis.